We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+8.48%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.8B
AUM Growth
+$629M
Cap. Flow
-$312M
Cap. Flow %
-2.1%
Top 10 Hldgs %
24.14%
Holding
917
New
50
Increased
256
Reduced
457
Closed
57

Top Buys

Rank Stock Value
1
VERU icon
Veru
VERU
+$53M
2
MELI icon
Mercado Libre
MELI
+$43.2M
3
DAR icon
Darling Ingredients
DAR
+$41.7M
4
JNJ icon
Johnson & Johnson
JNJ
+$33.7M
5
MET icon
MetLife
MET
+$31.1M

Top Sells

Rank Stock Value
1
PEP icon
PepsiCo
PEP
+$46.1M
2
NKE icon
Nike
NKE
+$36.6M
3
ITW icon
Illinois Tool Works
ITW
+$35.8M
4
AAPL icon
Apple
AAPL
+$31.9M
5
GILD icon
Gilead Sciences
GILD
+$29.8M

Sector Composition

Rank Sector Weight
1 Healthcare 33.32%
2 Technology 22.84%
3 Financials 10.04%
4 Consumer Discretionary 7.69%
5 Industrials 7.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVY icon
301
Avery Dennison
AVY
$12.8B
$8.54M 0.06%
47,158
+19,510
+71% +$3.48M
TFC icon
302
Truist Financial
TFC
$63.9B
$8.51M 0.06%
197,835
-10,606
-5% -$465K
FOLD
303
DELISTED
Amicus Therapeutics
FOLD
$8.47M 0.06%
693,879
+25,000
+4% +$281K
MU icon
304
Micron Technology
MU
$835B
$8.46M 0.06%
169,237
-265,458
-61% -$14.5M
BMO icon
305
Bank of Montreal
BMO
$123B
$8.39M 0.06%
92,712
-90,317
-49% -$8.36M
RXDX
306
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$8.25M 0.06%
75,000
-15,000
-17% -$973K
UNP icon
307
Union Pacific
UNP
$174B
$8.12M 0.05%
39,230
-4,765
-11% -$977K
ZBH icon
308
Zimmer Biomet
ZBH
$18.8B
$7.98M 0.05%
62,591
-16,047
-20% -$1.86M
FISV
309
Fiserv Inc
FISV
$29.7B
$7.78M 0.05%
76,989
-5,208
-6% -$519K
RUN icon
310
Sunrun
RUN
$2.26B
$7.76M 0.05%
323,110
+32,754
+11% +$874K
BLNK icon
311
Blink Charging
BLNK
$67.5M
$7.76M 0.05%
707,343
+240,842
+52% +$3.28M
PTCT icon
312
PTC Therapeutics
PTCT
$6.18B
$7.73M 0.05%
202,652
– –
NUVL
313
DELISTED
Nuvalent
NUVL
$7.7M 0.05%
+258,649
New +$7.21M
T icon
314
AT&T
T
$164B
$7.67M 0.05%
416,511
-27,041
-6% -$484K
CCI icon
315
Crown Castle
CCI
$34.6B
$7.52M 0.05%
55,463
-9,755
-15% -$1.32M
BLK icon
316
Blackrock
BLK
$167B
$7.49M 0.05%
10,577
+576
+6% +$385K
TRV icon
317
Travelers Companies
TRV
$81.1B
$7.43M 0.05%
39,631
-5,267
-12% -$947K
GE icon
318
GE Aerospace
GE
$364B
$7.36M 0.05%
141,062
-16,128
-10% -$793K
HSY icon
319
Hershey
HSY
$37.3B
$7.35M 0.05%
31,720
-1,932
-6% -$445K
DYN icon
320
Dyne Therapeutics
DYN
$4.15B
$7.34M 0.05%
633,624
+220,000
+53% +$2.55M
ORCL icon
321
Oracle
ORCL
$339B
$7.31M 0.05%
89,408
-10,313
-10% -$784K
LRCX icon
322
Lam Research
LRCX
$316B
$7.3M 0.05%
173,690
-24,410
-12% -$1.02M
SRE icon
323
Sempra
SRE
$58.1B
$7.19M 0.05%
93,072
-3,024
-3% -$234K
PLNT icon
324
Planet Fitness
PLNT
$4.45B
$7.18M 0.05%
91,069
+1,721
+2% +$120K
EVOP
325
DELISTED
EVO Payments, Inc. Class A Common Stock
EVOP
$7.11M 0.05%
210,156
+172,479
+458% +$5.8M
11 12
13
14 15

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q4 2022 Portfolio in Review

As of Q4 2022, Candriam SCA held 917 positions worth $14.8B, up 4.4% from $14.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Candriam SCA's Q4 2022 filing shows 50 new, 256 increased, 457 reduced and 57 closed positions. Its largest new stake was Sarepta Therapeutics: 95,144 shares worth $12.3M. The largest sale was PepsiCo, an estimated $46.1M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 32% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q4 2022 buy was Sarepta Therapeutics: 95,144 shares worth $12.3M.
  • Candriam SCA added most to Veru in Q4 2022, an estimated $53M increase.
  • Candriam SCA's biggest Q4 2022 reduction was PepsiCo, cutting an estimated $46.1M.
  • Candriam SCA fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $24.6M.
  • Candriam SCA's ten largest holdings make up 24% of its $14.8B portfolio in Q4 2022.
  • Candriam SCA opened 50 new positions and closed 57 in Q4 2022.
  • Candriam SCA's portfolio value rose 4.4% quarter-over-quarter to $14.8B.

Based on Candriam SCA's 13F filing for Q4 2022, filed 13 Feb 2023.